阿茲海默症治療市場、機會、成長動力、產業趨勢分析與預測，2024-2032

由於政府資金和支持的增加，阿茲海默症治療市場規模從 2024 年到 2032 年的複合年成長率預計將達到 9.8%。

世界各國政府正投入大量資金進行研發，旨在發現阿茲海默症的有效治療方法和潛在療法。這種財政支持使科學家能夠深入研究創新的治療途徑，包括藥物開發、基因治療和尖端診斷工具。此外，公共機構和私人實體之間加強的夥伴關係正在推動治療方案的進步。例如，2023年1月，美國FDA加速批准Leqembi（lecanemab-irmb）。這項認可標誌著在解決阿茲海默症核心病理學方面取得的關鍵進展。

阿茲海默症治療產業分為藥物類別、給藥途徑、配銷通路和地區。

由於越來越重視透過同時針對與疾病相關的多種途徑來提高治療效果，組合藥物類別的市場佔有率預計將在 2024 年至 2032 年實現強勁的複合年成長率。這些組合藥物利用不同的機制來解決阿茲海默症的各個方面，包括減少澱粉樣蛋白斑塊和增強認知功能。正在進行的研究正在深入研究這些多標靶藥物的潛力，表明它們可能提供超越傳統單一藥物療法的整體方法。

從配銷通路來看，阿茲海默症治療市場的線上藥局領域預計在2024 年至2032 年期間將出現顯著的複合年成長率。 。線上平台不僅提供一系列阿茲海默症治療方法，包括尖端療法，而且還確保增強隱私性以及訂購和交付的便利性，以顯著幫助患者管理自己的病情。

到 2032 年，亞太地區的阿茲海默症治療產業將實現大幅複合年成長率。隨著老年人口的增加，對有效治療的需求也會增加。作為回應，研究人員和醫療保健專業人員正在推出量身定做的治療方法，以滿足這個不斷擴大的人口的獨特需求。對抗阿茲海默症的加強關注不僅可以改善治療方案，還可以改善患者的治療效果，以確保在其患病率不斷上升的情況下更好地進行疾病管理。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

• 產業生態系統分析
• 產業影響力
  • 成長動力
    • 阿茲海默症的盛行率不斷增加
    • 診斷技術的進步
    • 意識和診斷率不斷提高
    • 優惠報銷政策
  • 產業陷阱與挑戰
    • 藥物研發成本高
    • 臨床試驗失敗率高
• 成長潛力分析
• 監管環境
• 管道分析
• 按疾病階段
• 波特的分析
• PESTEL分析
• 未來市場趨勢
• 差距分析

第 4 章：競爭格局

• 介紹
• 公司矩陣分析
• 供應商矩陣分析
• 競爭定位矩陣
• 戰略儀表板

第 5 章：市場估計與預測：按藥物類別，2021 - 2032 年

• 主要趨勢
• 膽鹼酯酶抑制劑
• NMDA受體拮抗劑
• 組合藥物
• 谷氨酸抑制劑
• 單胺氧化酶抑制劑
• 其他藥物類別

第 6 章：市場估計與預測：按管理途徑，2021 年至 2032 年

• 主要趨勢
• 口服
• 可注射
• 經皮貼劑

第 7 章：市場估計與預測：按配銷通路分類，2021 - 2032 年

• 主要趨勢
• 醫院藥房
• 零售藥房
• 網路藥房

第 8 章：市場估計與預測：按地區，2021 - 2032

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
  • 歐洲其他地區
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
  • 亞太地區其他地區
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地區
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 中東和非洲其他地區

第 9 章：公司簡介

• AbbVie Inc.
• Amgen Inc.
• AstraZeneca
• Biogen
• Cipla Inc.
• Daiichi Sankyo Company, Limited
• Eisai Co., Ltd.
• Eli Lilly and Company
• H. Lundbeck A/S
• Merck and Co., Inc.
• Novartis AG
• Otsuka Pharmaceutical Co., Ltd.
• Pfizer, Inc.
• Sanofi
• Sun Pharmaceutical Industries Ltd.

Alzheimer's Therapeutics Market size is set to record a 9.8% CAGR from 2024 to 2032 due to increased government funding and support.

Governments worldwide are channeling significant funds into R and D, aiming to discover effective treatments and potential cures for Alzheimer's disease. This financial backing empowers scientists to delve into innovative therapeutic avenues, encompassing drug development, gene therapy, and cutting-edge diagnostic tools. Furthermore, the strengthened partnerships between public institutions and private entities are propelling advancements in treatment options. For instance, in January 2023, the U.S. FDA granted accelerated approval to Leqembi (lecanemab-irmb). This endorsement signifies a pivotal advancement in addressing the core pathology of Alzheimer's disease.

The alzheimer's therapeutics industry is segmented into drug class, route of administration, distribution channel, and region.

The market share from the combination drug class segment is poised to witness a robust CAGR from 2024 to 2032 attributed to the growing emphasis on enhancing treatment efficacy by simultaneously targeting multiple pathways associated with the disease. These combination drugs leverage diverse mechanisms to tackle various facets of Alzheimer's, including reducing amyloid plaques and boosting cognitive functions. Ongoing research is delving into the potential of these multi-targeted agents, suggesting they might offer a holistic approach for outpacing traditional single-drug therapies.

By distribution channel, the online pharmacy segment of the alzheimer's therapeutics market is set to experience a notable CAGR from 2024 to 2032. This is fueled by the increasing consumer demand for convenient medication access. Online platforms are not only providing a spectrum of Alzheimer's treatments, including cutting-edge therapies but are also ensuring enhanced privacy and ease in ordering and delivery to significantly aid patients in managing their conditions.

Asia Pacific alzheimer's therapeutics industry will register a substantial CAGR through 2032. This growth is driven by an aging populace and the surging prevalence of Alzheimer's in the region. As the elderly population swells, the demand for effective treatments will also rise. In response, researchers and healthcare professionals are rolling out tailored therapeutics to meet the unique needs of this expanding demographic. The intensified focus on combating Alzheimer's is not only refining treatment options but also bolstering patient outcomes to ensure better disease management amidst its rising prevalence.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of Alzheimer's disease
    • 3.2.1.2 Technological advancements in diagnostics
    • 3.2.1.3 Growing awareness and diagnosis rates
    • 3.2.1.4 Favorable reimbursement policies
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of drug development
    • 3.2.2.2 High failure rate in clinical trials
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Pipeline analysis
• 3.6 By stage of disease
• 3.7 Porter's analysis
• 3.8 PESTEL analysis
• 3.9 Future market trends
• 3.10 GAP analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Vendor matrix analysis
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Cholinesterase inhibitors
• 5.3 NMDA receptor antagonist
• 5.4 Combination drugs
• 5.5 Glutamate inhibitors
• 5.6 MAO inhibitors
• 5.7 Other drug classes

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Oral
• 6.3 Injectable
• 6.4 Transdermal patch

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Hospital pharmacy
• 7.3 Retail pharmacy
• 7.4 Online pharmacy

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
  • 8.5.4 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 AbbVie Inc.
• 9.2 Amgen Inc.
• 9.3 AstraZeneca
• 9.4 Biogen
• 9.5 Cipla Inc.
• 9.6 Daiichi Sankyo Company, Limited
• 9.7 Eisai Co., Ltd.
• 9.8 Eli Lilly and Company
• 9.9 H. Lundbeck A/S
• 9.10 Merck and Co., Inc.
• 9.11 Novartis AG
• 9.12 Otsuka Pharmaceutical Co., Ltd.
• 9.13 Pfizer, Inc.
• 9.14 Sanofi
• 9.15 Sun Pharmaceutical Industries Ltd.